<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00190580</url>
  </required_header>
  <id_info>
    <org_study_id>620</org_study_id>
    <nct_id>NCT00190580</nct_id>
  </id_info>
  <brief_title>Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease</brief_title>
  <official_title>Effects of Valsartan on the Progression of Renal and Cardiovascular Disease - Kanagawa Valsartan Trial (KVT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KVT-Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tokai University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yokohama City University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Showa University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kitasato University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Marianna University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>KVT-Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to prove the hypothesis that the progression of renal and
      cardiovascular disease is more efficiently prevented when the angiotensin II receptor blocker
      valsartan is added to conventional antihypertensive therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is widely recognized that suppression of the renin-angiotensin system ameliorates
      progression of chronic kidney disease (CKD) and that CKD is an important risk factor for
      development of cardiovascular disease. However, it has not been fully clarified if
      amelioration of CKD leads to the lower incidence of cardiovascular disease. The purpose of
      this study is to determine whether the angiotensin II receptor antagonist valsartan, in
      combination with conventional antihypertensive therapy, will ameliorate progression of both
      CKD and cardiovascular disease. The primary outcome is courses of renal and cardiac function.
      The secondary outcome is a composite of a doubling of serum creatinine concentration,
      end-stage renal disease, myocardial infarction, coronary revascularization, stroke,
      hospitalization for unstable angina, hospitalization for heart failure or death from
      cardiovascular causes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Course of renal and cardiac function</measure>
    <time_frame>every month for renal function and every year for cardiac function</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Doubling of serum creatinine concentration</measure>
    <time_frame>every month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-stage renal disease</measure>
    <time_frame>anytime when it occurs.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>anytime when it occurs.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary revascularization</measure>
    <time_frame>anytime when it occurs.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>anytime when it occurs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for unstable angina</measure>
    <time_frame>anytime when it occurs.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for heart failure</measure>
    <time_frame>anytime when it occurs.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from cardiovascular causes</measure>
    <time_frame>anytime when it occurs.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">312</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valsartan</intervention_name>
    <description>valsartan, dosage from 20mg to 180mg, once or twice a day plus conventional antihypertensive drugs</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Diovan 40mg or Diovan 80mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional antihypertensive drugs</intervention_name>
    <description>Conventional antihypertensive drugs including calcium channel blockers, diuretics, angiotensin converting enzyme inhibitors and/or beta-blockers</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>any antihypertensive drug except ARB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CKD with serum creatinine more than 2.0 mg/dl

          -  Blood pressure more than 130/85 mmHg

          -  20 years old or above

        Exclusion Criteria:

          -  End-stage renal disease with maintenance dialysis

          -  Polycystic kidney disease

          -  Collagen disease

          -  Malignant or accelerated hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenjiro Kimura, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Marianna University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Marianna University School of Medicine</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>KVT-Study Group</investigator_affiliation>
    <investigator_full_name>Kenjiro Kimura</investigator_full_name>
    <investigator_title>Professor of St. Marianna University School of Medicine</investigator_title>
  </responsible_party>
  <keyword>CKD</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>hypertension</keyword>
  <keyword>angiotensin II receptor blocker</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>valsartan</keyword>
  <keyword>KVT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

